EW Stock Recent News
EW LATEST HEADLINES
SAN DIEGO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Edwards Lifesciences Corporation (NYSE: EW) securities between February 6, 2024 and July 24, 2024, inclusive (the “Class Period”), have until December 13, 2024 to seek appointment as lead plaintiff of the Edwards Lifesciences class action lawsuit. Captioned Patel v. Edwards Lifesciences Corporation, No. 24-cv-02221 (C.D. Cal.), the Edwards Lifesciences class action lawsuit charges Edwards Lifesciences and certain of Edwards Lifesciences' top executives with violations of the Securities Exchange Act of 1934.
NEW YORK, NY / ACCESSWIRE / October 14, 2024 / If you suffered a loss on your Edwards Lifesciences Corporation (NYSE:EW) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/edwards-lifesciences-lawsuit-submission-form?prid=108401&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / October 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Edwards Lifesciences Corporation ("Edwards Lifesciences") (NYSE:EW) concerning possible violations of federal securities laws. On October 28, 2022, Edwards announced 3Q 2022 financial results that missed revenue estimates and then lowered revenue guidance for the 4Q.
NEW YORK, NY / ACCESSWIRE / October 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Edwards Lifesciences Corporation ("Edwards Lifesciences") (NYSE:EW) concerning possible violations of federal securities laws. On October 28, 2022, Edwards announced 3Q 2022 financial results that missed revenue estimates and then lowered revenue guidance for the 4Q.
NEW YORK, NY / ACCESSWIRE / October 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Edwards Lifesciences Corporation ("Edwards Lifesciences") (NYSE:EW) concerning possible violations of federal securities laws. On October 28, 2022, Edwards announced 3Q 2022 financial results that missed revenue estimates and then lowered revenue guidance for the 4Q.
Edwards Lifescience (EW, Financial), a medical device company that specializes in cardiovascular, today by soaring 6% to $68.49 per share at the time this article was written. Technical analysis suggests that it's the moment of “strong buy”.
NEW YORK, NY / ACCESSWIRE / October 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Edwards Lifesciences Corporation ("Edwards Lifesciences") (NYSE:EW) concerning possible violations of federal securities laws. On October 28, 2022, Edwards announced 3Q 2022 financial results that missed revenue estimates and then lowered revenue guidance for the 4Q.
Investors interested in Medical - Instruments stocks are likely familiar with Teleflex (TFX) and Edwards Lifesciences (EW). But which of these two companies is the best option for those looking for undervalued stocks?
NEW YORK, NY / ACCESSWIRE / September 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Edwards Lifesciences Corporation ("Edwards Lifesciences") (NYSE:EW) concerning possible violations of federal securities laws. On October 28, 2022, Edwards announced 3Q 2022 financial results that missed revenue estimates and then lowered revenue guidance for the 4Q.
NEW YORK, NY / ACCESSWIRE / September 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Edwards Lifesciences Corporation ("Edwards Lifesciences") (NYSE:EW) concerning possible violations of federal securities laws. On October 28, 2022, Edwards announced 3Q 2022 financial results that missed revenue estimates and then lowered revenue guidance for the 4Q.